Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555.

Published

Journal Article

Pharmacological blockade of either nicotinic or muscarinic cholinergic receptors has been found to impair choice accuracy in the radial-arm maze. Simultaneous blockade of both of these receptor types causes an additive impairment. However, despite these common effects, nicotinic and muscarinic receptors have been found to have differential involvement with dopamine receptors. The cognitive impairment caused by the muscarinic antagonist scopolamine is reversed by the D1 antagonist SCH 23390 but is unaffected by the D2 antagonist raclopride. In contrast, the cognitive impairment caused by the nicotinic antagonist mecamylamine is unaffected by SCH 23390 but is potentiated by raclopride. In the current study, the D2 agonist LY 171555 was found to be effective in reversing the radial-arm maze choice accuracy impairment caused by mecamylamine. In contrast, the D1 agonist SKF 38393 was not found to be effective. Thus, we have found selective dopaminergic D1 and D2 treatments which counteract the adverse cognitive effects of either nicotinic or muscarinic blockade. A combination of these treatments may be useful in treating the cognitive effects of generalized cholinergic underactivation.

Full Text

Duke Authors

Cited Authors

  • Levin, ED; McGurk, SR; Rose, JE; Butcher, LL

Published Date

  • August 1, 1989

Published In

Volume / Issue

  • 33 / 4

Start / End Page

  • 919 - 922

PubMed ID

  • 2575760

Pubmed Central ID

  • 2575760

International Standard Serial Number (ISSN)

  • 0091-3057

Language

  • eng

Conference Location

  • United States